ELV Earnings

85, including the Company's estimate of the financial impact for the CMS matter • FY 2026 adjusted diluted EPS 2 guidance raised to at least $26.75, supported by underlying business strength, actions to reduce medical costs, and increased visibility • Reaffirm FY 2026 operating cash flow of at lea

"Our first quarter results exceeded expectations, reflecting underlying business strength and improving claims experience. We are raising our full-year adjusted EPS guidance, supported by greater visibility into the balance of the year. Our actions are driving more consistent performance and position Elevance Health for continued improvement over t

onference Call and Webcast Management will host a conference call and webcast today at 8:30 a.m. Eastern Daylight Time (“EDT”) to discuss the company’s first quarter results and outlook. The conference call should be accessed at least 15 minutes prior to the start of the call with the following numbers: 888-947-9963 (Domestic) 800-391-9853 (Domestic Replay) 31

officers will reaffirm adjusted shareholders’ earnings for full year 2026 to be at least $25.50 per diluted share. The Company also will reaffirm its 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points. As reported in a Current Report on Form 8-K filed by the Company on March 2, 2026, the Company was notified by the Centers for Medicare

ings and benefit expense ratio guidance set forth above includes the impact of the Sanctions, if imposed. At this time, the Company is unable to provide a reconciliation of its guidance for adjusted shareholders’ earnings per diluted share for full year 2026 to shareholders’ earnings per diluted share for full year 2026, the most directly comparable GAAP finan